Clinical trial
Pollution, Isotonic Nasal Wash, NSAID Evaluation (PINE)
NCT07925229 is registered in ClinicalTrials.gov with University of British Columbia as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Not yet recruiting, started December 2026. Interventional study, Phase 4, 20 participants (estimated). Lead sponsor University of British Columbia; Canada. Primary measures: Effects of wood smoke on airway inflammation with Advil and Otrivin: FeNO; Effects of wood smoke on airway inflammation with Advil and Otrivin: Cytokines and Oxylipins and 2 more.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Pollution, Isotonic Nasal Wash, NSAID Evaluation (PINE)
- Lead sponsor
- University of British Columbia
- Phase
- Phase 4
- Overall status
- Not yet recruiting
- Start date
- December 31, 2026
- Completion date
- December 31, 2029
- Enrollment
- 20 (estimated)
- Sites
- 1
Conditions
As the registry lists them.
this study will evaluate the effects of woodsmoke exposures and advil in healthy adults
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 19 Years
- Maximum age
- 80 Years
- Healthy volunteers
- Yes
- Study type
- Interventional
- Sites
- 1
- Countries
- Canada
- Lead sponsor
- University of British Columbia
Arms
As registered; 4 arms.
| Arm | Type | Interventions |
|---|---|---|
| Filtered Air exposure with Placebo | Placebo comparator | Filtered Air exposure, Placebo Pill |
Show registry wordingParticipants will be exposed to high-efficiency particulate air (HEPA) filtered air for 2 hours, and will take a placebo both before, and 3, 10, 22 hours after. | ||
| Filtered Air exposure with Advil (Ibuprofen) | Experimental | Filtered Air exposure, Ibuprofen (Advil 400 mg x 4) |
Show registry wordingParticipants will be exposed to high-efficiency particulate air (HEPA) filtered air for 2 hours and will take Advil (Ibuprofen 400mg) both before, and 3, 10 and 22 hours after. | ||
| Wood Smoke exposure with Placebo | Experimental | Placebo Pill, Wood Smoke (Lodgepole Pine) exposure |
Show registry wordingParticipants will be exposed to wood smoke, standardized to 500µg/m3 of PM2.5, for 2 hours and will take a placebo both before, and 3, 10 and 22 hours after. | ||
| Wood Smoke exposure with Advil (Ibuprofen) | Experimental | Ibuprofen (Advil 400 mg x 4), Wood Smoke (Lodgepole Pine) exposure |
Show registry wordingParticipants will be exposed to wood smoke, standardized to 500µg/m3 of PM2.5, for 2 hours and will take Advil (Ibuprofen 400mg) both before, and 3, 10 and 22 hours after. | ||
Primary endpoints
Registered primary outcome measures; 4 primary.
| Measure | Time frame |
|---|---|
| Effects of wood smoke on airway inflammation with Advil and Otrivin: FeNO | Comparison of the different arms over the span of 5 months. |
Show registry wordingMeasurement of fractional exhaled nitric oxide (FeNO). | |
| Effects of wood smoke on airway inflammation with Advil and Otrivin: Cytokines and Oxylipins | Comparison of the different arms over the span of 5 months. |
Show registry wordingAn inflammation matrix will be generated, including data from nasal inflammatory cytokines and oxylipins, with independent collection from each nostril. | |
| Effects of wood smoke exposure on airflow and resistance in the airways with Advil and Otrivin: PNIF | Comparison of the different arms over the span of 5 months. |
Show registry wordingMeasure nasal patency using peak nasal inspiratory flow (PNIF) analysis. | |
| Effects of wood smoke exposure on airflow and resistance in the airways with Advil and Otrivin: Oscillometry | Comparison of the different arms over the span of 5 months. |
Show registry wordingDetermine small airways function/resistance using oscillometry. | |
Patents and exclusivity
By drug, as the FDA Orange Book declares its patents.
-
IBUPROFEN
- US 11806400; expires March 16, 2032; assignee Cumberland Pharmaceuticals Inc
- US 9072661; expires March 16, 2032; assignee Cumberland Pharmaceuticals Inc
- US 9072710; expires March 16, 2032; assignee Cumberland Pharmaceuticals Inc
- US 9012508; expires September 14, 2030; assignee Cumberland Pharmaceuticals Inc
- US 8735452; expires September 30, 2029; assignee Cumberland Pharmaceuticals Inc
- +5 more patents
Lead sponsor's other trials
University of British Columbia, most recent start first.
+1,334 more trials See the organization page